Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: A Spanish National Healthcare System perspective

Biblos-e Archivo/Manakin Repository

Files in this item

Thumbnail
Share

Delicious Save this on Delicious

Citations

This item appears in the following Collection(s)